Other previous studies on Oligo-PD after PD-1/PD-L1 inhibitor treatment in patients with NSCLC have also not identified the benefits of LAT for patients with Oligo-PD [56,57]. This evidence concerns the gene LAT and non-small cell lung carcinoma.